ATE432987T1 - Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums - Google Patents

Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums

Info

Publication number
ATE432987T1
ATE432987T1 AT07001711T AT07001711T ATE432987T1 AT E432987 T1 ATE432987 T1 AT E432987T1 AT 07001711 T AT07001711 T AT 07001711T AT 07001711 T AT07001711 T AT 07001711T AT E432987 T1 ATE432987 T1 AT E432987T1
Authority
AT
Austria
Prior art keywords
present
methods
polypeptides
compositions
cell growth
Prior art date
Application number
AT07001711T
Other languages
German (de)
English (en)
Inventor
Avi J Ashkenazi
Audrey Goddard
Paul J Godowski
Austin L Gurney
Scot A Marsters
Mary A Napier
Robert M Pitti
William I Wood
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/en
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE432987T1 publication Critical patent/ATE432987T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT07001711T 1998-12-22 1999-12-02 Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums ATE432987T1 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US11329698P 1998-12-22 1998-12-22
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
US13023299P 1999-04-21 1999-04-21
US13144599P 1999-04-28 1999-04-28
US13428799P 1999-05-14 1999-05-14
US14475899P 1999-07-20 1999-07-20
US14569899P 1999-07-26 1999-07-26
PCT/US1999/021547 WO2000015797A2 (en) 1998-09-17 1999-09-15 Compositions and methods for the treatment of immune related diseases
PCT/US1999/021090 WO2000015796A2 (en) 1998-09-16 1999-09-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Publications (1)

Publication Number Publication Date
ATE432987T1 true ATE432987T1 (de) 2009-06-15

Family

ID=27557838

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07001711T ATE432987T1 (de) 1998-12-22 1999-12-02 Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums
AT04007617T ATE353339T1 (de) 1998-12-22 1999-12-02 Verfahren und zusammensetzung zur hemmung des neoplastischen zellwachstums

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04007617T ATE353339T1 (de) 1998-12-22 1999-12-02 Verfahren und zusammensetzung zur hemmung des neoplastischen zellwachstums

Country Status (13)

Country Link
EP (1) EP1141284A2 (enExample)
JP (5) JP3993746B2 (enExample)
KR (1) KR100499600B1 (enExample)
AT (2) ATE432987T1 (enExample)
AU (1) AU768230B2 (enExample)
CA (1) CA2353799A1 (enExample)
DE (2) DE69935085T2 (enExample)
DK (1) DK1484338T3 (enExample)
ES (2) ES2281704T3 (enExample)
IL (3) IL143031A0 (enExample)
MX (1) MXPA01006330A (enExample)
PT (1) PT1484338E (enExample)
WO (1) WO2000037638A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066041A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
US6392019B1 (en) 1997-11-22 2002-05-21 John Ford Antibodies specific for EGF motif proteins
US6808890B2 (en) 1999-07-28 2004-10-26 Nuvelo, Inc. Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
JP2002504308A (ja) 1997-11-22 2002-02-12 ハイセック インコーポレイテッド 胎児肝−脾臓のｃＤＮＡライブラリーから得られた新規ＥＧＦモチーフタンパク質
EP1251139A3 (en) * 1998-04-08 2002-12-18 Genentech, Inc. Human mindin-like protein and nucleic acids encoding it
US6960433B1 (en) 1998-10-19 2005-11-01 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU2507700A (en) 1999-01-15 2000-08-01 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
AU768694B2 (en) * 1999-03-08 2004-01-08 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU4011300A (en) * 1999-07-20 2001-02-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
MXPA02005758A (es) * 1999-12-09 2002-09-18 Sankyo Co Metodo para evaluar un remedio o agente preventivo para hiperlipidemia.
PL356887A1 (en) * 2000-01-12 2004-07-12 Yale University Nogo receptor-mediated blockade of axonal growth
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
US6943146B2 (en) 2000-05-08 2005-09-13 Biogen Idec Ma Inc. Method for promoting neovascularization
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
DE60141409D1 (de) 2000-10-06 2010-04-08 Biogen Idec Inc Homologe des nogo rezeptors
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
SI1997512T1 (sl) 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Postopki za zdravljenje stanj, povezanih s TWEAK-om
CA2391438A1 (en) * 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP1904091A4 (en) 2005-07-07 2009-12-23 Univ Yale COMPOSITIONS AND METHODS FOR SUPPRESSING THE INHIBITION OF AXON GROWTH
ES2551202T5 (es) 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
EP2010226B1 (en) * 2006-04-07 2014-01-15 The Research Foundation of State University of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US7776573B2 (en) 2006-06-01 2010-08-17 Genentech, Inc. Crystal structure of CRIg and C3b:CRIg complex
CN106084054A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
LT2280996T (lt) 2008-05-06 2016-12-12 Genentech, Inc. Subrendusio giminingumo crig variantai
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
CN114835774B (zh) * 2022-06-29 2022-09-27 中国农业大学 辣椒籽分离的寡肽msl及其在预防或治疗癌症中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
US5028099A (en) * 1990-08-08 1991-07-02 Bertucco Leonard J Trash recycling container
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU3661199A (en) * 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
JP7039446B2 (ja) * 2018-11-29 2022-03-22 株式会社東芝 電子装置

Also Published As

Publication number Publication date
EP1141284A2 (en) 2001-10-10
DK1484338T3 (da) 2007-06-11
JP2007291116A (ja) 2007-11-08
DE69940964D1 (de) 2009-07-16
JP2005237383A (ja) 2005-09-08
IL186153A0 (en) 2008-01-20
JP2005245451A (ja) 2005-09-15
ES2327785T3 (es) 2009-11-03
DE69935085D1 (de) 2007-03-22
CA2353799A1 (en) 2000-06-29
KR20010084882A (ko) 2001-09-06
KR100499600B1 (ko) 2005-07-07
PT1484338E (pt) 2007-05-31
JP3993746B2 (ja) 2007-10-17
ES2281704T3 (es) 2007-10-01
IL143031A0 (en) 2002-04-21
WO2000037638A3 (en) 2000-11-09
ATE353339T1 (de) 2007-02-15
JP4037876B2 (ja) 2008-01-23
JP2003529317A (ja) 2003-10-07
AU1749900A (en) 2000-07-12
AU768230B2 (en) 2003-12-04
DE69935085T2 (de) 2007-08-23
WO2000037638A2 (en) 2000-06-29
MXPA01006330A (es) 2002-07-02
JP2007222180A (ja) 2007-09-06
IL186154A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
ATE432987T1 (de) Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums
ATE357518T1 (de) Verfahren und zusammensetzungen zur inhibierung des neoplastischen zellwachstums
ATE408419T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
ATE380195T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
IL193149A (en) Anti il-17c antibody and therapeutic compositions comprising same
WO2002026822A3 (en) Pumpcn compositions and uses thereof
ATE397063T1 (de) Fibroblasten-wachstumsfaktor-19
ATE444971T1 (de) Zusammensetzungen und verfahren für die tumor- behandlung
ATE427319T1 (de) Zusammensetzung und verfahren zur diagnose von tumoren
WO2000032778A3 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2001049715A3 (en) Methods and compositions for inhibiting neoplastic cell growth
EP2075335A3 (en) Methods and compositions for inhibiting neoplastic cell growth
EP1820860A3 (en) Methods and compositions for inhibiting neoplastic cell growth
KR100515858B1 (en) PRO617 Polypeptides
WO2000007545A3 (en) Apoptosis proteins
KR100515857B1 (en) PRO792 Polypeptides
KR100515856B1 (en) PRO618 Polypeptides
KR100515855B1 (en) PRO351 Polypeptides
DK1249491T3 (da) Nucleinsyre, der opformeres i humane tumorer samt beslægtede materialer og fremgangsmåder

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties